SCHEMBL6482166

SCHEMBL6482166

COc1ccccc1CNc1ccc2c(c1)Oc1ccccc1S2

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.52
KMT2A Q03164 2/20 0.52
HIF1A Q16665 2/20 0.47
KDM4E B2RXH2 6/20 0.45
MAPT P10636 6/20 0.45
ALDH1A1 P00352 6/20 0.45
GAA P10253 5/20 0.45
MAPK1 P28482 4/20 0.45
L3MBTL1 Q9Y468 3/20 0.45
ALOX15 P16050 2/20 0.45
TSHR P16473 2/20 0.45
HTT P42858 1/20 0.45
TDP1 Q9NUW8 1/20 0.45
HSD17B10 Q99714 2/20 0.43
CYP3A4 P08684 2/20 0.43
CYP2C9 P11712 2/20 0.43
CYP2C19 P33261 2/20 0.43
NPSR1 Q6W5P4 1/20 0.43
HPGD P15428 1/20 0.42
EGFR P00533 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6493342 0.91 MAPT (0.54) MEN1KMT2AHIF1AKDM4EMAPT
SCHEMBL6495927 0.88 HIF1A (0.53) MEN1KMT2AHIF1AKDM4EMAPT
SCHEMBL6482929 0.88 MAPT (0.54) MEN1KMT2AKDM4EMAPTALDH1A1
SCHEMBL6483812 0.84 MEN1 (0.59) MEN1KMT2AHIF1AKDM4EMAPT
SCHEMBL6491982 0.83 MAPT (0.43) MEN1KMT2AKDM4EMAPTALDH1A1
SCHEMBL6482832 0.82 MAPT (0.43) MEN1KMT2AHIF1AKDM4EMAPT
SCHEMBL6484335 0.81 HIF1A (0.48) MEN1KMT2AHIF1AKDM4EMAPT
SCHEMBL6494125 0.81 MAPT (0.51) MEN1KMT2AHIF1AKDM4EMAPT
SCHEMBL6495422 0.81 UTS2R (0.40) MEN1KMT2AKDM4EMAPTALDH1A1
SCHEMBL6491909 0.81 FFAR1 (0.44) MEN1KMT2AMAPTGAAL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050075332-A1 Tricyclic compounds with antiviral activity WARNER LAMBERT COMPANY 2005-04-07 US claimed
US-20030229073-A1 Tricyclic compounds and method of treating herpes virus BOOTH RICHARD JOHN (US) 2003-12-11 US claimed
EP-1248777-A2 TRICYCLIC COMPOUNDS WITH ANTIVIRAL ACTIVITY WARNER-LAMBERT COMPANY (US) 2002-10-16 EP claimed
WO-2001051479-A2 TRICYCLIC COMPOUNDS WITH ANTIVIRAL ACTIVITY WARNER-LAMBERT COMPANY (US) 2001-07-19 WO claimed
US-20050075332-A1 Tricyclic compounds with antiviral activity WARNER LAMBERT COMPANY 2005-04-07 US disclosed
US-6800656-B2 Tricyclic compounds and method of treating herpes virus WARNER LAMBERT COMPANY 2004-10-05 US disclosed
US-20030229073-A1 Tricyclic compounds and method of treating herpes virus BOOTH RICHARD JOHN (US) 2003-12-11 US disclosed
EP-1248777-A2 TRICYCLIC COMPOUNDS WITH ANTIVIRAL ACTIVITY WARNER-LAMBERT COMPANY (US) 2002-10-16 EP disclosed
WO-2001051479-A2 TRICYCLIC COMPOUNDS WITH ANTIVIRAL ACTIVITY WARNER-LAMBERT COMPANY (US) 2001-07-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030229073-A1 Tricyclic compounds and method of treating herpes virus HDAC8, ZC3HAV1, ZCCHC8 MEN1 3995/4885KMT2A 412/4885HIF1A 3185/4885
US-20050075332-A1 Tricyclic compounds with antiviral activity HDAC8, CDK8, ZC3HAV1 MEN1 3464/4885KMT2A 770/4885HIF1A 1519/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.